Graded English news article at C1 level.
Researchers at the Massachusetts Institute of Technology and Massachusetts Eye and Ear Infirmary have reported unprecedented success in a gene therapy trial that restored partial hearing in children born with a rare genetic form of deafness. The therapy, which involves a single injection into the inner ear, delivers a functional copy of the OTOF gene responsible for producing a protein critical to sound signal transmission between hair cells and the auditory nerve. Of the twelve children treated between ages two and six, nine showed measurable improvement in hearing within three months. The remaining three showed moderate improvement after six months. The trial, published in the New England Journal of Medicine, represents a potential paradigm shift in treating congenital hearing loss, which affects approximately 34 million children worldwide. Regulatory agencies in both the United States and Europe have granted the therapy fast-track designation.
This piece is graded at CEFR level C1, it belongs to science, published on 2026-07-23.
پژوهشگران مؤسسه فناوری ماساچوست و بیمارستان چشم و گوش ماساچوست موفقیت بیسابقهای در یک آزمایش ژندرمانی گزارش کردهاند که شنوایی را در کودکان متولد شده با یک نوع نادر ژنتیکی ناشنوایی بازگرداند. این درمان شامل یک تزریق واحد به گوش داخلی است.
More graded english news on lienguaflow.ir/news — free English practice for Persian speakers.